Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers September 2, 2014
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - September 2, 2014

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 57     Next >>     Go To Page:

8/31/14 - B. Braun Receives FDA Approval for Nutrilipid 20%
By a News Reporter-Staff News Editor at Medical Letter on the CDC& FDA B. Braun Medical Inc., a leader in infusion therapy and pain management, announced that it has received U.S. Food and Drug Administration approval of Nutrilipid 20% for parenteral nutrition therapy in adult& pediatric patients. "We are very pleased that the FDA has granted ap
8/31/14 - Sanofi Pasteur Announces Publication of Positive Data for Fluzone High-Dose Vaccine in The New England Journal of Medicine
By a News Reporter-Staff News Editor at Medical Letter on the CDC& FDA Sanofi Pasteur, the vaccines division of Sanofi, announced that The New England Journal of Medicine published positive results from a large-scale, multi-center efficacy trial, which found that Fluzone High-Dose was more efficacious in preventing influenza in adults 65 years of
8/30/14 - Avion Pharmaceuticals, LLC, signs Captisol License Agreement with Ligand Pharmaceuticals to develop four new products
By a News Reporter-Staff News Editor at Marketing Weekly News Avion Pharmaceuticals, LLC, announces the signing of a commercial license agreement with Ligand Pharmaceuticals Incorporated for the development and commercialization of four Captisol-enabled programs. "We are very pleased to formalize this new partnership with Ligand and the...
8/29/14 - An Application for the Trademark "MILPROSA" Has Been Filed by Teva Pharmaceuticals USA
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a trademark application has been made for "MILPROSA" by Herschel Perel, representing Teva Pharmaceuticals USA. The owner/registrar information for this application is: Herschel Perel, Teva Pharmaceuticals USA, 42
8/29/14 - Data on Immunoglobulins Reported by Researchers at Biogen Idec, Inc. (Recommendations for the characterization of immunogenicity response to multiple...
Data on Immunoglobulins Reported by Researchers at Biogen Idec, Inc.. In a common tier based approach, samples identified as ADA screen positive are confirmed for the binding specificity of the antibodies to the drug molecule via a confirmatory assay. The confirmation of specificity is generally considered as a critical step of the tier based appro
8/29/14 - Forward Pharma Announces Appointment of Dr. Jan G. J. van de Winkel to Board of Directors
By a News Reporter-Staff News Editor at Health& Medicine Week Forward Pharma A/S, a biopharmaceutical company focused on a proprietary formulation of dimethyl fumarate for the treatment of multiple sclerosis, announced that it has appointed Jan van de Winkel, Ph.D, President and Chief Executive Officer of Genmab, to its Board of Directors, effect
8/29/14 - Recent Studies from University of Nebraska Add New Data to Medicinal Chemistry (The Current State of Drug Discovery and a Potential Role for NMR...
Recent Studies from University of Nebraska Add New Data to Medicinal Chemistry. According to news reporting originating from Lincoln, Nebraska, by NewsRx editors, the research stated, "The pharmaceutical industry has significantly contributed to improving human health. Our news editors obtained a quote from the research from the University of Nebra
8/28/14 - Drug Delivery in Cancer 2014: Technologies, Markets and Companies
By a News Reporter-Staff News Editor at Gene Therapy Weekly Research and Markets has announced the addition of Jain PharmaBiotech's new report "Drug Delivery in Cancer- Technologies, Markets and Companies" to their offering. Drug delivery remains a challenge in management of cancer. Approximately 12.5 million new cases of cancer are being diagnos
8/28/14 - Patent Application Titled "Pharmaceutical Injection Device" Published Online
By a News Reporter-Staff News Editor at Politics& Government Week According to news reporting originating from Washington, D.C., by VerticalNews journalists, a patent application by the inventors Kondoh, Tsuguhiro; Kikuchi, Seiji; Hanada, Takashi, filed on September 10, 2012, was made available online on August 14, 2014. The assignee for this pat
8/28/14 - Researchers Submit Patent Application, "Phytocannabinoids for Use in the Treatment of Cancer", for Approval
By a News Reporter-Staff News Editor at Women's Health Weekly From Washington, D.C., NewsRx journalists report that a patent application by the inventors Ross, Ruth Alexandra; Parolaro, Daniela, filed on September 10, 2012, was made available online on August 14, 2014. The patent's assignee is Otsuka Pharmaceutical Co., Ltd.. News editors obtaine
8/28/14 - Studies from Federal University Have Provided New Information about Science and Public Policy (Brazilian pharmaceutical industry and generic drugs...
Our news editors obtained a quote from the research from Federal University, "In this paper, we evaluate the unplanned impacts from the introduction of generic drugs, particularly with respect to the business scale and innovation. For more information on this research see: Brazilian pharmaceutical industry and generic drugs policy: Impacts on struc
8/28/14 - Valeant Pharmaceuticals Receives FTC Second Request Under Hart-Scott-Rodino
By a News Reporter-Staff News Editor at Politics& Government Week Valeant Pharmaceuticals International, Inc. announced that the Company has received a request for additional information from the Federal Trade Commission in connection with Valeant's proposed acquisition of Allergan, Inc.. About Valeant Pharmaceuticals International, Inc..
8/27/14 - "Two-Stage Reconstituting Injector" in Patent Application Approval Process
By a News Reporter-Staff News Editor at Biotech Week A patent application by the inventors KRAMER, Thomas E.; SADOWSKI, Peter L., filed on April 4, 2014, was made available online on August 14, 2014, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to Antares Pharma, Inc.
8/27/14 - Access Pharmaceuticals Awarded Japan Patent For MuGard And ProctiGard
By a News Reporter-Staff News Editor at Biotech Week ACCESS PHARMACEUTICALS, INC., an emerging biopharmaceutical company, has received notification from the Japan Patent Office that a patent for MuGard and ProctiGard has been granted. "Following our recent European licensing agreement with Norgine, the strengthening of our world-wide intellectua
8/27/14 - Amgen Announces Top-Line Results From Phase 3 Focus Trial Of Kyprolis In Patients With Relapsed And Advanced Refractory Multiple Myeloma
By a News Reporter-Staff News Editor at Biotech Week Amgen and its subsidiary, Onyx Pharmaceuticals, Inc., announced that the Phase 3 clinical trial FOCUS did not meet its primary endpoint of improving overall survival. "While it is unfortunate that the FOCUS study did not meet its primary endpoint of overall survival, we believe the results fro
8/27/14 - Array Biopharma Inc. Files SEC Form 3, Initial Statement of Beneficial Ownership of Securities [Amend] (Aug. 7, 2014)
By a News Reporter-Staff News Editor at Biotech Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Array Biopharma Inc. was posted on August 7, 2014. The SEC file number is 0001104659-14-058442.. A U.S. Securities and Exchange Commission filing is a formal
8/27/14 - Array Biopharma Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities [Amend] (Aug. 7, 2014)
By a News Reporter-Staff News Editor at Biotech Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Array Biopharma Inc. was posted on August 7, 2014. The SEC file number is 0001104659-14-058444.. A U.S. Securities and Exchange Commission filing is a formal
8/27/14 - Array Biopharma Inc. Files SEC Form 8-K, Current Report (Aug. 12, 2014)
By a News Reporter-Staff News Editor at Biotech Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Array Biopharma Inc. was posted on August 12, 2014. The SEC file number is 0001100412-14-000036.. A U.S. Securities and Exchange Commission filing is a forma
8/27/14 - Catalent Confirms the Appointment of Two Senior Healthcare Executives to Its Board of Directors
By a News Reporter-Staff News Editor at Journal of Engineering Catalent, Inc., the global leader in drug development solutions and advanced delivery technologies for pharmaceutical, biologic, and consumer health products, announced that it has appointed Jack Stahl and Rolf Classon to its Board of Directors. Mr. Classon currently serves as Chairma
8/27/14 - Endonovo Therapeutics Developing Non-Invasive Bioelectronic Therapy for Urinary Incontinence
By a News Reporter-Staff News Editor at Biotech Week Endonovo Therapeutics, Inc., a developer of non-invasive bioelectronic therapies, announced that it has retained Holland& Knight, LLP as its legal counsel and Emergo Group, Inc. to assist the Company in obtaining FDA clearance of its non-invasive urinary incontinence treatment. Holland& Knight
8/27/14 - FDA Approves Genentech's Avastin Plus Chemotherapy for Treatment of Advanced Cervical Cancer
By a News Reporter-Staff News Editor at Biotech Week Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration approved Avastin in combination with paclitaxel and cisplatin or paclitaxel and topotecan for the treatment of women with persistent, recurrent or metastatic carcinoma of the cervix. "With this appr
8/27/14 - Flex Pharma Announces Positive Results from Human Clinical Studies
By a News Reporter-Staff News Editor at Biotech Week Flex Pharma, Inc., a biopharmaceutical company dedicated to creating innovative, novel treatments for neuromuscular disorders, announced positive clinical results of its proprietary product for preventing muscle cramps. With these positive results in healthy volunteers, we plan to initiate effi
8/27/14 - Galena Biopharma, Inc. Files SEC Form 10-Q, Quarterly Report [Sections 13 Or 15(D)] (Aug. 11, 2014)
By a News Reporter-Staff News Editor at Biotech Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Galena Biopharma, Inc. was posted on August 11, 2014. The SEC file number is 0001390478-14-000043.. A U.S. Securities and Exchange Commission filing is a for
8/27/14 - Galena Biopharma, Inc. Files SEC Form 8-K, Current Report (Aug. 11, 2014)
By a News Reporter-Staff News Editor at Biotech Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Galena Biopharma, Inc. was posted on August 11, 2014. The SEC file number is 0001390478-14-000042.. A U.S. Securities and Exchange Commission filing is a for
8/27/14 - Gene Therapy - Technologies, Markets and Companies - 2014-2023
By a News Reporter-Staff News Editor at Vaccine Weekly Research and Markets has announced the addition of Jain PharmaBiotech's new report "Gene Therapy- Technologies, Markets and Companies" to their offering. Since the death of Jesse Gelsinger in the US following a gene therapy treatment, the FDA has further tightened the regulatory control on ge
Articles(s): 1 - 25 of 57     Next >>     Go To Page:


© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

The Diversion of Controlled Substances and the Law
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comPharmacyPages.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415